April 1, 2021 | Targeted Therapies in Oncology

Lessons Learned From COVID-19— 1 Year Later

April 18, 2021

Clinical Articles

The pandemic brought about by severe acute respiratory syndrome coronavirus 2 has put some aspects of life on hold for over a year now. However, for people living with serious and potentially fatal illnesses, putting life on hold is not an option.

Ceralasertib/Durvalumab Combination Stands Out in HUDSON Trial for Patients With NSCLC

April 17, 2021

Clinical Articles

For patients non–small cell lung cancer who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.

Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma

April 15, 2021

Clinical Articles

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

Lenalidomide Reduces Infection Mortality Rates in COVID-19-Positive Patients With Multiple Myeloma

April 13, 2021

Clinical Articles

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

Afatinib Shows Encouraging Efficacy and Safety in Late Stage EGFR-Mutant NSCLC

April 08, 2021

Clinical Articles

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.

Neratinib Is Effective Against EGFR Exon 18 Mutations in NSCLC

April 06, 2021

Clinical Articles

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Twice Daily Poziotinib Beats Safety of Single Dose in NSCLC

April 05, 2021

Clinical Articles

Perliminary analyses of 2 cohorts from the phase 2 multicohort ZENITH20 trial evaluating poziotinib show clinical activity and tolerability for the tyrosine kinase inhibitor in patients with non–small cell lung cancer harboring EGFR and HER2 exon 20 insertions.